---
trial_id: 260
discovery_date: 2022-03-29 21:28:28.008278
date: 2022-03-29 21:28:28.008278
title: "A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS"
summary: |
  <p>EudraCT Number: 2020-000893-69<br />Sponsor Protocol Number: BN42082<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-10-28<br />Medical condition: Relapsing Multiple Sclerosis (MS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/NL">NL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/FR">FR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/IT">IT</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000893-69'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2020-000893-69<br />Sponsor Protocol Number: BN42082<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-10-28<br />Medical condition: Relapsing Multiple Sclerosis (MS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/NL">NL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/FR">FR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/IT">IT</a> (Ongoing)</p>